Search for content, post, videos

Novo Nordisk invests 850 million DKK in production facilities

Novo Nordisk Kalundborg

Novo Nordisk has announced plans to invest DKK 850 million in expanding its production facilities in Kalundborg, Denmark.

This new investment brings Novo Nordisk’s total investments in site Kalundborg to more than DKK 2 billion in 2020. Novo Nordisk currently manufactures a range of diabetes care products in Kalundborg, and the new investment will be used to rebuild and expand an existing production facility to create additional capacity for manufacturing the pharmaceuticals of the future, states the company.

“We have 50 years’ expertise in Kalundborg, and from the turn of the millennium until 2019 alone, Novo Nordisk invested more than DKK 16 billion in the Kalundborg facility. This year we have announced several additional investments, underscoring Novo Nordisk’s ambition to continue strengthening its presence in Denmark and Kalundborg,” says Michael Hallgren, senior vice president and head of production, Novo Nordisk Kalundborg.

Previous investments

In February, Novo Nordisk announced an investment of DKK 800 million in upgrading and expanding facilities at its production site in Kalundborg to ensure capacity for future production of existing and new-generation diabetes care products. In May, the company announced a further investment of DKK 150 million in a new tablet packaging production line, followed up in June by an investment of DKK 225 million.

Photo Kalundborg: Novo Nordisk